…survival and objective response rate also demonstrated statistical significance. Tivdak (tisotumab vedotin) is an antibody-drug conjugate (ADC) composed of Genmab’s human monoclonal antibody directed to tissue factor and Seagen’s ADC…
…Gen Li, founder and CEO of Phesi. “Without diverse patient cohorts that accurately reflect the patient population a drug is intended for, we cannot ensure that drugs will be fully…
…drug delivery” as part of its Transforming Medicines Manufacturing programme. Dr James Dixon, Associate Professor of the School of Pharmacy and NIHR Nottingham Biomedical Research Centre at University of Nottingham,…
…with the potential for meaningful differentiation from existing standard-of-care treatments.” Joanna Shields, Chief Executive Officer of BenevolentAI, said: “Our AI powered drug discovery platform identified PDE10 as a novel target…
A new eBook is now available from Malvern Panalytical: ‘Faster, more accurate and deeper insight: How to make the switch to label-free interaction analysis.’ Label-free interaction analysis takes discovery to…
…of drug and gene therapies’ will take place on 28 September 4PM BST, 5PM CEST, EDT 11AM, PDT 8AM. Register for free here. Speakers: Chris Kirton, Chief Executive Officer, DefiniGEN…
…of innovative approaches to disease being employed by researchers across the globe. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts….
…bench to bedside, lab to patient. Technology is increasingly important to drug discovery. Advances in this area are having a positive effect on both the commercial success of drug discovery…
…science space further supports our company’s culture and focus on nurturing breakthrough discoveries.” Edited by Diana Spencer, Senior Digital Content Editor, Drug Discovery World Image shows: Canary Wharf, London, UK….
…University of Arizona Cancer Center, Stacie Lindsey, CCF Founder and CEO, and Melinda Bachini, CCF Director of Patient Services. Edited by Diana Spencer, Senior Digital Content Editor, Drug Discovery World…
…disease has shown promise in early clinical trials. FDA fast-tracks monoclonal antibody for head and neck cancer Fast Track designation from the Food and Drug Administration (FDA) will accelerate the…
The BioInnovation Institute (BII) has welcomed three new drug discovery start-ups into its Venture Lab acceleration programme as part of its latest cohort of eight companies. The 12-month Venture Lab…
…risks, and improving trial outcomes. Enhancing understanding of drug behaviour, toxicity, and efficacy in humans. The potential to revolutionise drug development by optimising dose selection. Download the whitepaper for free….
…aiming to further develop aspects of his programme focusing on targeting EXD2 nuclease in cancer in collaboration with industry. Edited by Diana Spencer, Senior Digital Content Editor, Drug Discovery World…
Evox Therapeutics, an exosome therapeutics company, has published Evox-funded research identifying novel exosome scaffold proteins that significantly improve drug loading into exosomes for therapeutic purposes in Nature Communications. This follows…
